Ningjia Zhou
YOU?
Author Swipe
View article: IMMU-24. CHEK2 haploinsufficiency drives immune responsiveness in aggressive meningiomas
IMMU-24. CHEK2 haploinsufficiency drives immune responsiveness in aggressive meningiomas Open
Meningiomas account for more than 30% of all primary central nervous system (CNS) tumors. Although approximately 80% of meningiomas are benign (WHO Grade 1), the remaining 20%, which include Grade 2 and 3 tumors, exhibit poor progression-f…
View article: Targeting CHEK2-YBX1&YBX3 regulatory hub to potentiate immune checkpoint blockade response in gliomas
Targeting CHEK2-YBX1&YBX3 regulatory hub to potentiate immune checkpoint blockade response in gliomas Open
Although GBM’s immunosuppressive environment is well known, the tumor’s resistance to CD8+ T cell killing is not fully understood. Our previous study identified Checkpoint Kinase 2 (Chek2) as the key driver of CD8+ T cell resistance in mou…